Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.60 |
| ▸ | PPARG | P37231 | 10/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24037243 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL30341699 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL12065748 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL29746744 | 0.86 | PPARG (0.55) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL8659023 | 0.84 | IDO1 (0.68) | PPARAPPARGPPARDIDO1ACE | |
| SCHEMBL19888241 | 0.84 | SLC17A5 (0.58) | SLC17A5MDM2 | |
| SCHEMBL24037465 | 0.83 | IDO1 (0.48) | IDO1SLC17A5ACEALDH1A1MAPT | |
| SCHEMBL12707588 | 0.82 | SLC17A5 (0.47) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL2399667 | 0.82 | SLC17A5 (0.47) | PPARAPPARGPPARDIDO1SLC17A5 | |
| SCHEMBL9514163 | 0.82 | PPARG (0.51) | PPARAPPARGPPARDIDO1SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | disclosed |
| US-20210355132-A1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2021-11-18 | — | — | US | disclosed |
| US-7947671-B2 | Synthesis of naturally occuring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| EP-2305689-A1 | The synthesis of naturally occuring ecteinascidins and related compounds | Pharma Mar S.A.U. (ES) | 2011-04-06 | — | — | EP | disclosed |
| US-7795260-B2 | Synthesis of naturally occurring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2010-09-14 | — | — | US | disclosed |
| US-20100216987-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | BARRASA VALENTIN MARTINEZ | 2010-08-26 | — | — | US | disclosed |
| US-7767659-B2 | Synthesis of naturally occurring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2010-08-03 | — | — | US | disclosed |
| US-20090163507-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20070093658-A1 | Synthesis of naturally occcuring ecteinascidins and related compounds | PHARMA MAR, S.A. (ES) | 2007-04-26 | — | — | US | disclosed |
| US-5821329-A | Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion | TANABE SEIYAKU CO., LTD. (JP) | 1998-10-13 | — | — | US | disclosed |
| WO-1996040781-A1 | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355132-A1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | TMED9, EMD, ENTPD8 | PPARA 3873/4885PPARG 3804/4885PPARD 3583/4885 |
| US-20100216987-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | NQO1, HCCS, NME1 | PPARA 3998/4885PPARG 3947/4885PPARD 3827/4885 |
| US-20070093658-A1 | Synthesis of naturally occcuring ecteinascidins and related compounds | NQO1, EDF1, RCN1 | PPARA 4494/4885PPARG 4274/4885PPARD 4175/4885 |
| US-20090163507-A1 | SYNTHESIS OF NATURALLY OCCURING ECTEINASCIDINS AND RELATED COMPOUNDS | NQO1, HCCS, NME1 | PPARA 3998/4885PPARG 3947/4885PPARD 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.